In a phase 1/2 trial in 26 males with Duchenne muscular dystrophy amenable to exon 44 skipping, adverse events occurred in 84% on del-zota vs 86% on placebo; two stopped (one anaphylaxis, one infusion reaction). Dystrophin rose about 25% with del-zota vs −0·7% with placebo.
RCTn = 26
Veerapandiyan et al. Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial